An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

Maky Zanganeh became a billionaire after shares of Summit Therapeutics, where she serves as co-CEO, soared following positive ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...